The goal of this clinical research study is to learn about the safety of adding MDPL3280A to
standard chemotherapy (a combination of carboplatin and paclitaxel) and radiation in patients
with lung cancer.
You are being asked to take part in this study because you have non-small cell lung cancer
(NSCLC) that is unresectable (cannot be removed by surgery) and has not spread.
This is an investigational study. MPDL3280A is not FDA approved or commercially available. It
is currently being used for research purposes only. Paclitaxel, carboplatin, and the
radiation therapy are all FDA approved for the treatment of lung cancer. The use of these
drugs in combination is considered investigational.
Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.